Treatment of refractory Her-2 positive metastatic young breast cancer with pyrrolidine combined with capecitabine: a case report
10.3760/cma.j.cn101721-20200720-00020
- VernacularTitle:吡咯替尼联合卡培他滨治疗难治性Her-2阳性转移性年轻乳腺癌患者一例
- Author:
Xiangxin ZHENG
;
Ji WU
;
Shucheng GU
;
Xiaoling JIANG
;
Xiaohong SHI
;
Mu YUAN
;
Bolin LU
;
Xing QIU
;
Xuxu ZHANG
;
Jianyin BAI
;
Peng YANG
;
Xiaoqing GUAN
- From:
Clinical Medicine of China
2021;37(3):226-228
- CountryChina
- Language:Chinese
-
Abstract:
In order to explore the treatment of Her-2 positive breast cancer patients who failed in multi-line treatments, we retrospectively analyzed the clinical data of a patient with refractory Her-2 positive breast cancer.The patient was initially diagnosed as Her-2 positive advanced breast cancer.After six line treatment in the outer hospital, the patient′s condition was basically in a progressive state.The breast tumor was broken and purulent, the lung metastasis increased, and the patient′s quality of life was poor.The patient was admitted to Department of Breast Surgery of Affiliated Suqian Hospital of Xuzhou Medical University, after MDT discussion, we gave pyrrolotinib combined with capecitabine treatment, the chest wound healed gradually, the lung metastasis gradually reduced, and the quality of life was better.A retrospective analysis of this case showed that pyrrolidine combined with capecitabine may bring hope to Her-2 positive breast cancer patients who failed to receive multi-line therapies, especially those who failed to target therapy.
